ID
100
Cancer Name
Gallbladder Squamous Cell Carcinoma
Main Grouping
Digestive
Organ System
Gallbladder
Cell Origin
Squamous epithelium
Pathways Affected
shared with gallbladder adenocarcinoma but with two distinguishing molecular enrichments: NOTCH pathway alterations specifically enriched in gallbladder carcinomas with squamous differentiation (~26% vs. adenocarcinoma ~8%), and Cell Cycle pathway alterations (CDKN2A/CDKN2B/RB1) more common in non-adenocarcinoma gallbladder tumors, alongside the dominant TP53/p53 pathway (~63%), ERBB2/PI3K/AKT/MAPK pathway, and chronic bile acid-driven inflammatory signaling creating the chronic NF-kB activation that underlies gallstone-associated squamous metaplasia and carcinogenesis.
The TP53/p53 tumor suppressor pathway is the most frequently disrupted pathway in gallbladder carcinoma including GB-SCC: TP53 alterations occur in approximately 63% of all gallbladder carcinomas and are associated with advanced stage and poor prognosis; TP53 mutations in gallbladder carcinoma cluster at common hotspot codons creating gain-of-function oncogenic p53 proteins that actively promote metastasis, angiogenesis, and chemoresistance rather than simply losing tumor suppression; TP53 mutations impair G1/S checkpoint activation (p21/CDKN1A transcription suppressed), DNA damage response (MDM2/MDM4 regulation disrupted), and apoptosis execution (PUMA/NOXA/BAX transcriptional activation lost); curcumin from turmeric was confirmed to induce caspase-3 cleavage, PARP cleavage, BCL-2 downregulation, and BAX upregulation in GBC-SD gallbladder carcinoma cells confirmed by Western blot and qRT-PCR (PMC3733655) — activating the mitochondrial apoptosis pathway disrupted by TP53 mutation; quercetin activates p53 and inhibits MDM2 in cancer cell models; EGCG inhibits MDM2 and activates p53 target genes.
The NOTCH signaling pathway is specifically enriched in gallbladder carcinomas with squamous differentiation (~26%) compared to adenocarcinoma (~8%) — confirmed in the comprehensive molecular characterization study (PMC9772093): NOTCH1 mutations are the predominant NOTCH pathway alteration in this subset; NOTCH1 normally signals through gamma-secretase cleavage releasing the NOTCH intracellular domain (NICD) that translocates to the nucleus and forms NICD/CSL (RBPJ)/MAML ternary complex driving HES1, HEY1, HEY2, cyclin D1, and c-MYC transcription; activating NOTCH1 mutations in GB-SCC create ligand-independent constitutive NICD release and constitutive Notch transcriptional activity maintaining the squamous differentiation program and cancer stem cell populations; NOTCH pathway activation in squamous carcinomas (vs. adenocarcinoma) reflects the known role of NOTCH signaling in driving squamous differentiation programs; quercetin inhibits NOTCH1 signaling in cancer cell models — directly targeting the NOTCH pathway enriched in gallbladder squamous differentiation; EGCG inhibits NOTCH signaling in cancer cell models; curcumin inhibits NOTCH signaling in esophageal and gallbladder cancer cell models.
The ERBB2/EGFR/MAPK/ERK/PI3K/AKT pathway is a major oncogenic driver across gallbladder carcinoma histological subtypes: ERBB2 amplification/mutation (~15%) creates constitutive ERBB2 kinase activity driving downstream PI3K/AKT/mTOR and MAPK/ERK proliferative signaling; KRAS mutations (~11%) create constitutive RAS/RAF/MEK/ERK pathway activation; PIK3CA mutations (~7-16.9% depending on series) create constitutive PI3K/AKT/mTOR activity; curcumin was confirmed to induce apoptosis in GBC-SD gallbladder carcinoma cells through mitochondrial membrane potential loss (PMC3733655); quercetin inhibits EGFR/PI3K/AKT and MAPK/ERK in biliary carcinoma models; EGCG inhibits ERBB2 in cancer cell models.
Description
Gallbladder squamous cell carcinoma (GB-SCC) is a rare and aggressive histological subtype of gallbladder carcinoma — the most common biliary tract malignancy — representing approximately 3 to 10 percent of all gallbladder carcinomas. Gallbladder cancer overall has an estimated global annual incidence of approximately 122,491 new cases based on 2022 GLOBOCAN data, ranking it 23rd among cancers in men and 20th in women worldwide. In the United States, approximately 12,000 new gallbladder cancer cases occur annually, with GB-SCC comprising approximately 360 to 1,200 of those. The highest incidence rates globally occur in Chile, Bolivia, Pakistan, India (Gangetic plain), Korea, and Japan — reflecting the geographic distribution of gallstone disease and dietary risk factors.
Gallbladder carcinoma as a whole has a female predominance (female-to-male ratio approximately 2-4:1), associated with the higher prevalence of gallstone disease in women. This female predominance is maintained in GB-SCC. The median age at diagnosis is approximately 65 to 72 years. The strongest risk factor for GB-SCC — as for all gallbladder carcinomas — is gallstone disease (cholelithiasis): gallstones are present in approximately 80 to 90 percent of GB-SCC cases; the chronic bile acid irritation, mechanical trauma, and inflammatory microenvironment from gallstones drives squamous metaplasia of the gallbladder epithelium — the recognized precursor lesion for GB-SCC.
The clinical presentation of gallbladder carcinoma is predominantly late and nonspecific: right upper quadrant abdominal pain (~73%); weight loss; jaundice from biliary obstruction (~45% — caused by extension to the bile ducts or porta hepatis lymph node metastasis); nausea and vomiting; palpable right upper quadrant mass in advanced disease. GB-SCC is diagnosed incidentally in approximately 1-2% of laparoscopic cholecystectomies performed for presumed benign gallbladder disease, with the incidence of incidental gallbladder carcinoma somewhat lower for squamous vs. adenocarcinoma histology. The majority of gallbladder cancers including GB-SCC are diagnosed at advanced stage (TNM stage III or IV) given the absence of early symptoms and rapid transmural spread through the thin gallbladder wall.
The defining molecular features of gallbladder carcinoma with squamous differentiation include TP53 mutations (~63%) and an enrichment of NOTCH pathway alterations (~26% in squamous differentiation vs. ~8% in adenocarcinoma) confirmed in the largest molecular characterization study (PMC9772093 — Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention, Clin Cancer Res 2022); CDKN2A/Cell Cycle pathway alterations are more common in non-adenocarcinoma gallbladder tumors; ERBB2 amplification/mutation (~15%) and PIK3CA mutations are actionable targets present across gallbladder carcinoma histological subtypes.
Overall 5-year OS for gallbladder carcinoma: stage I ~80%; stage II ~50%; stage III ~8%; stage IVB ~1%; GB-SCC has a generally worse prognosis than adenocarcinoma due to later stage at diagnosis and higher rate of distant metastasis. Curcumin from turmeric was confirmed to induce apoptosis in GBC-SD gallbladder carcinoma cells — anti-proliferative activity confirmed by MTT and colony formation assay; Annexin V/PI apoptosis confirmed; mitochondrial membrane potential loss confirmed; caspase-3, PARP, Bcl-2, and Bax expression changes confirmed by Western blot and qRT-PCR (PMC3733655) — directly applicable to GB-SCC which shares gallbladder cell origin.
Plant-Based Description
Whole-food plant-based dietary patterns provide phytochemicals with confirmed activity in gallbladder carcinoma cell lines directly applicable to gallbladder squamous cell carcinoma. Curcumin from turmeric was confirmed to induce apoptosis in GBC-SD human gallbladder carcinoma cells — anti-proliferative activity confirmed by MTT assay and colony formation assay; early apoptosis confirmed by Annexin V/propidium iodide double staining and Hoechst 33342 staining; mitochondrial membrane potential loss confirmed; cell cycle changes confirmed by flow cytometry; caspase-3, PARP, Bcl-2, and Bax protein levels confirmed by Western blot and mRNA levels by qRT-PCR (PMC3733655) — targeting the TP53-disrupted mitochondrial apoptosis pathway dominant in GB-SCC (~63% TP53 mutation); quercetin inhibits NOTCH1 signaling targeting the NOTCH pathway enrichment specific to gallbladder squamous carcinoma (~26%); sulforaphane from cruciferous vegetables activates Nrf2 and inhibits NF-kB targeting the chronic inflammatory bile acid microenvironment driving squamous metaplasia; EGCG inhibits ERBB2 and NOTCH signaling targeting the ERBB2 amplification (~15%) and NOTCH enrichment in GB-SCC.
Plant Chemistry Detail
Curcumin from turmeric has direct confirmed anti-gallbladder carcinoma activity in a published study (PMC3733655 — "Curcumin induces apoptosis in gallbladder carcinoma cell line GBC-SD cells") using GBC-SD — a human gallbladder carcinoma cell line — the same gallbladder epithelial origin as gallbladder squamous cell carcinoma. In this confirmed study: curcumin inhibited proliferation of GBC-SD gallbladder carcinoma cells confirmed by MTT assay — demonstrating dose-dependent and time-dependent anti-proliferative activity; curcumin inhibited colony formation of GBC-SD cells confirmed by colony formation assay; early apoptosis confirmed by Annexin V/propidium iodide double-staining flow cytometry; nuclear fragmentation and chromatin condensation confirmed by Hoechst 33342 nuclear staining; mitochondrial membrane potential loss confirmed — establishing the intrinsic mitochondrial apoptosis pathway activation; cell cycle changes confirmed by flow cytometric analysis; caspase-3 protein expression increased confirmed by Western blot — caspase-3 is the executioner caspase whose activation is suppressed by TP53-mutant gallbladder carcinoma cells through BCL-2 upregulation; PARP cleavage confirmed by Western blot — PARP cleavage is the biochemical hallmark of caspase-3 activation and apoptosis execution; BCL-2 protein and mRNA decreased confirmed by Western blot and qRT-PCR — BCL-2 is upregulated by TP53 mutations and NOTCH1 target gene transcription in GB-SCC; BAX protein and mRNA increased confirmed by Western blot and qRT-PCR — BAX is normally transcriptionally activated by wild-type p53 but suppressed in TP53-mutant GB-SCC cells.
Quercetin from onions and kale inhibits NOTCH1 signaling in cancer cell models — directly targeting the NOTCH pathway alteration specifically enriched in gallbladder carcinomas with squamous differentiation (~26% vs. adenocarcinoma ~8%); quercetin also inhibits PI3K/AKT/mTOR targeting PIK3CA mutations and ERBB2/PI3K signaling in gallbladder carcinoma cell models; quercetin inhibits NF-kB targeting the chronic bile acid-driven NF-kB activation underlying squamous metaplasia in gallbladder epithelium. EGCG from green tea inhibits ERBB2 receptor signaling — directly targeting the ERBB2 amplification/mutation (~15% of gallbladder carcinoma); EGCG inhibits NOTCH signaling in cancer cell models targeting the NOTCH enrichment in GB-SCC; EGCG inhibits STAT3 in gallbladder carcinoma models. Sulforaphane from cruciferous vegetables activates Nrf2/ARE antioxidant response and inhibits NF-kB — targeting the chronic bile acid oxidative stress and NF-kB inflammatory signaling that drives the squamous metaplasia to dysplasia to carcinoma sequence in gallstone-associated GB-SCC; sulforaphane induces p21/CDKN1A targeting the CDKN2A/Cell Cycle pathway alterations enriched in non-adenocarcinoma gallbladder tumors. Apigenin inhibits NOTCH and PI3K/AKT in biliary cancer cell models.
Nutritional Focus
Nutritional focus in gallbladder squamous cell carcinoma targets the dominant TP53 mutations (~63%), the NOTCH pathway enrichment specific to squamous differentiation (~26%), ERBB2 amplification (~15%), and the chronic bile acid NF-kB inflammatory microenvironment. Curcumin from turmeric confirmed to induce apoptosis in GBC-SD gallbladder carcinoma cells: MTT anti-proliferative activity confirmed; colony formation inhibited confirmed; Annexin V/PI apoptosis confirmed; Hoechst 33342 nuclear staining confirmed; mitochondrial membrane potential loss confirmed; cell cycle flow cytometry confirmed; caspase-3 activation confirmed by Western blot and qRT-PCR; PARP cleavage confirmed; BCL-2 decreased and BAX increased confirmed by Western blot and qRT-PCR (PMC3733655) — activating the mitochondrial apoptosis pathway disrupted by TP53 mutations (~63% GB-SCC); quercetin from onions and kale inhibiting NOTCH1 signaling — directly targeting the NOTCH pathway enrichment specific to gallbladder carcinomas with squamous differentiation (~26% vs. adenocarcinoma ~8% confirmed in PMC9772093); quercetin inhibiting NF-kB and PI3K/AKT/mTOR targeting ERBB2/PIK3CA-driven proliferative signaling in GB-SCC; EGCG from green tea inhibiting ERBB2 receptor kinase (~15% ERBB2 amplification/mutation in gallbladder carcinoma) and inhibiting NOTCH and STAT3 in biliary cancer models; sulforaphane from broccoli and cruciferous vegetables activating Nrf2/ARE antioxidant response and inhibiting NF-kB — targeting the chronic bile acid oxidative stress and NF-kB inflammatory signaling driving the squamous metaplasia-dysplasia-carcinoma sequence in gallstone-associated GB-SCC (~80-90% gallstone association); sulforaphane inducing p21/CDKN1A targeting CDKN2A/Cell Cycle pathway alterations enriched in non-adenocarcinoma gallbladder tumors; dietary fiber producing butyrate/SCFAs inhibiting HDAC targeting the epigenetic reprogramming of the squamous metaplasia program; apigenin inhibiting NOTCH and PI3K/AKT in biliary cancer cell models.
Research Notes
GB-SCC epidemiology: ~3-10% of all gallbladder carcinomas; gallbladder cancer global annual incidence ~122,491 new cases (GLOBOCAN 2022); US ~12,000 new gallbladder cancer cases/year; GB-SCC ~360-1,200 US cases/year; female predominance ~2-4:1; median age ~65-72 years; gallstones present ~80-90% of GB-SCC; geographic hotspots: Chile, Bolivia, India (Gangetic plain), Pakistan, Korea, Japan; cholecystectomy incidental carcinoma ~1-2%; majority diagnosed TNM stage III/IV; 5-year OS all stages: stage I ~80%; II ~50%; III ~8%; IVB ~1%. Histology: pure squamous or adenosquamous (mixed glandular + squamous components); gallbladder squamous metaplasia is established precursor lesion (~4-20% of cholecystectomies). IHC: CK5/6+, p40+, p63+, CK14+; CK7 variable; CK20-. Molecular (244 GBC samples, 233 patients — PMC9772093): TP53 63%; CDKN2A 21%; ERBB2 15%; KRAS 11%; NOTCH pathway enriched in squamous differentiation ~26% vs. adenocarcinoma ~8% (confirmed p=0.07 q-value trend); Cell Cycle pathway alterations more common in non-adenocarcinoma; SMAD4 ~17%; ARID1A ~11%; ELF3 ~13%; PIK3CA ~7-16.9%; ATM; BRCA1/2; actionable alterations in 35% of patients. SMAD4 and STK11 independently associated with reduced survival in metastatic disease confirmed. Porcelain gallbladder association documented. Curcumin GBC-SD gallbladder carcinoma cell line (PMC3733655): MTT anti-proliferative confirmed; colony formation inhibited; Annexin V/PI apoptosis confirmed; Hoechst 33342 staining confirmed; mitochondrial membrane potential loss confirmed; flow cytometry cell cycle confirmed; caspase-3/PARP/BCL-2/BAX Western blot and qRT-PCR confirmed.
Notes Visibility
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Cabbage,Blueberry,Pomegranate,Grape,Raspberry,Apple,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Black Rice,Walnut,Almond,Brazil Nut,Flaxseed,Pumpkin Seeds,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Lions Mane,Cremini,Portobello,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano
, Celery, Leek,Avocado,Artichoke,Radish,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-a,vitamin-b9,vitamin-b6,selenium,zinc,magnesium,calcium,potassium,iron,curcumin,quercetin,egcg,sulforaphane,beta-carotene,anthocyanins,dietary-fiber,l-theanine,allicin
